meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced OC (mOC) - 2nd line (L2)
3
immune chekpoint inhibitors
anti-PD-(L)1
avelumab based treatment
avelumab alone
avelumab plus pegylated liposomal doxorubicin
Immune checkpoint association
nivolumab plus ipilimumab
versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs anthracyclines
vs doxorubicin
vs pegylated liposomal doxorubicin
vs immune chekpoint inhibitors
vs anti-PD-(L)1
vs nivolumab based treatment
vs nivolumab alone
All patients
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
objective responses (ORR)
progression or deaths (PFS)
AE (grade 3-4)
AE leading to death (grade 5)
TRAE (grade 3-4)
TRAE leading to death (grade 5)
Acute kidney injury TRAE (grade 3-4)
Adrenal insufficiency TRAE (grade 3-4)
Anaemia TRAE (grade 3-4)
Arthritis TRAE (grade 3-4)
Colitis TRAE (grade 3-4)
Dyspnoea TRAE (grade 3-4)
Fatigue TRAE (grade 3-4)
Hyperthyroidism TRAE (grade 3-4)
Hypothyroidism TRAE (grade 3-4)
Nausea TRAE (grade 3-4)
Neutropenia TRAE (grade 3-4)
Pancreatitis TRAE (grade 3-4)
Pneumonitis TRAE (grade 3-4)
Pyrexia TRAE (grade 3-4)
Rash TRAE (grade 3-4)
Thrombocytopenia TRAE (grade 3-4)
deaths (OS)
metastatic/advanced OC (mOC) - 2nd line (L2)
metastatic/advanced OC (mOC) - 2nd line (L2)
versus nivolumab alone
nivolumab plus ipilimumab vs. nivolumab alone
1
certainty unassessable
-19%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open